Total Valuation
Alnylam Pharma has a market cap or net worth of €20.79B. The enterprise value is €33.47B.
Market Cap€20.79B
Enterprise Value€33.47B
Share Statistics
Alnylam Pharma has 133,809,110 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding133,809,110
Owned by Insiders0.24%
Owned by Institutions0.96%
Financial Efficiency
Alnylam Pharma’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is 13.74%.
Return on Equity (ROE)0.40
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)13.74%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee1.49M
Profits Per Employee125.50K
Employee Count2,500
Asset Turnover0.75
Inventory Turnover8.19
Valuation Ratios
The current PE Ratio of Alnylam Pharma is 8.5. Alnylam Pharma’s PEG ratio is -0.79.
PE Ratio8.5
PS Ratio14.03
PB Ratio66.01
Price to FCF111.94
Price to Operating Cash Flow25.82
PEG Ratio-0.79
Income Statement
In the last 12 months, Alnylam Pharma had revenue of 3.71B and earned 313.75M in profits. Earnings per share was 2.39.
Revenue3.71B
Gross Profit3.04B
Operating Income501.58M
Pretax Income323.15M
Net Income313.75M
EBITDA631.44M
Earnings Per Share (EPS)2.39
Cash Flow
In the last 12 months, operating cash flow was 650.37M and capital expenditures -149.64M, giving a free cash flow of 500.73M billion.
Operating Cash Flow650.37M
Free Cash Flow500.73M
Free Cash Flow per Share3.74
Dividends & Yields
Alnylam Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.33
52-Week Price Change-58.72%
50-Day Moving Average209.22
200-Day Moving Average246.76
Relative Strength Index (RSI)24.61
Average Volume (3m)38.00
Important Dates
Alnylam Pharma upcoming earnings date is Feb 18, 2027, Before Open (Confirmed).
Last Earnings DateOct 29, 2026
Next Earnings DateFeb 18, 2027
Ex-Dividend Date―
Financial Position
Alnylam Pharma as a current ratio of 2.76, with Debt / Equity ratio of 35.02%
Current Ratio2.76
Quick Ratio2.71
Debt to Market Cap0.02
Net Debt to EBITDA-0.60
Interest Coverage Ratio1.99
Taxes
In the past 12 months, Alnylam Pharma has paid 9.40M in taxes.
Income Tax9.40M
Effective Tax Rate0.03
Enterprise Valuation
Alnylam Pharma EV to EBITDA ratio is 81.90, with an EV/FCF ratio of 111.12.
EV to Sales13.92
EV to EBITDA81.90
EV to Free Cash Flow111.12
EV to Operating Cash Flow98.68
Balance Sheet
Alnylam Pharma has €3.59B in cash and marketable securities with €1.26B in debt, giving a net cash position of €2.33B billion.
Cash & Marketable Securities€3.59B
Total Debt€1.26B
Net Cash€2.33B
Net Cash Per Share€17.38
Tangible Book Value Per Share€6.02
Margins
Gross margin is 55.41%, with operating margin of 13.51%, and net profit margin of 8.45%.
Gross Margin55.41%
Operating Margin13.51%
Pretax Margin8.70%
Net Profit Margin8.45%
EBITDA Margin17.00%
EBIT Margin15.50%
Analyst Forecast
The average price target for Alnylam Pharma is €297.09, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€297.09
Price Target Upside19.17% Upside
Analyst ConsensusModerate Buy
Analyst Count26
Revenue Growth Forecast82.33%
EPS Growth Forecast―